Human Plasma-derived Therapeutics Obtained with PPPS Technology
ProMetic’s Plasma Protein Purification System (“PPPS”), originally developed in a co-venture with the American Red Cross, applies ProMetic’s Mimetic Ligand™ technology to provide for total and highly efficient extraction of proteins from human plasma. This system employs powerful affinity separation materials in a multi-step process to extract and purify proteins at high yields.
In 2008, Kedrion, a specialist in plasma-derived products based in Italy, in-licenced ProMetic’s yield improving technology for incorporation into its manufacturing process for the production of a Hepatitis B Hyperimmune, a product for which ProMetic retains the marketing rights in North America. The estimated value, expected to commence in 2011, is at minimum $30 million annually. WIBP, a subsidiary of CNBG, signed a strategic alliance and licence with ProMetic to access its yield improving manufacturing technology. The implementation of the product development plan, which is underway, includes training, technology transfer, scale-up and the readying of WIBP’s clinical manufacturing facility. Full scale commercial manufacturing will take place at WIBP initially, and could be readily implemented by other affiliated companies within CNBG later. WIBP is expected to process in excess of 1.2 million liters of plasma annually with ProMetic’s technology and commercialize seven plasma-derived life saving drugs in China. With its rapid economic growth, China is poised to become the world’s fourth largest domestic market for pharmaceuticals. With more than 9,000 employees and revenues of US$421 M in 2006, CNBG is the largest producer of vaccines and blood derivatives in China, having more than 80 and 30 percent market share respectively. This agreement, together with ProMetic’s contract with Blue Blood for Taiwan and South East Asian markets, have provided the Company with a major foothold in one of the world’s fastest growing markets.
For more information, please contact us.